BioCentury | Jul 21, 2014
Clinical News

Nalbuphine ER: Phase II/III started

...rights to the compound from Endo, which gained the rights through its 2010 acquisition of Penwest Pharmaceuticals Co....
BioCentury | Jul 14, 2014
Clinical News

Nalbuphine ER: Phase I data

...to the product in 2011 from Endo, which gained rights from its 2010 acquisition of Penwest Pharmaceuticals Co....
BioCentury | Jun 5, 2014
Financial News

Trevi closes $15 million of $25 million series B

...from Endo International plc (NASDAQ:ENDP; TSX:ENL), which gained the rights from its 2010 acquisition of Penwest Pharmaceuticals Co....
BioCentury | May 13, 2013
Clinical News

Nalbuphine ER: Phase I started

...the compound in 2011 from Endo, which gained the rights from its 2010 acquisition of Penwest Pharmaceuticals Co....
BioCentury | Jan 14, 2013
Emerging Company Profile

Trevi: Pain to itch

...from Endo Health Solutions Inc. , which gained the rights from its 2010 acquisition of Penwest Pharmaceuticals Co....
...submitted patent applications covering the oral formulation of nalbuphine and the method of treating pruritus. Penwest...
...CEO of Penwest. Good said she and Trevi CMO Thomas Sciascia, who was CMO at Penwest...
BioCentury | Oct 8, 2012
Product Development

Boosting mitochondria

...Penwest Therapeutics Inc., but Miller said that deal ended when Endo Health Solutions Inc. acquired Penwest...
BioCentury | Aug 27, 2012
Finance

Seeking alpha

...Corp. (NASDAQ:EPCT), which he helped take public in 2006, and president of drug delivery play Penwest Pharmaceuticals Co....
BioCentury | Sep 27, 2010
Company News

Endo, Penwest deal

...Endo completed its initial tender offer for Penwest, acquiring about 30.8 million shares (82.8%) at $5...
...complete next quarter (see BioCentury, Aug. 16). Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP), Chadds Ford, Pa. Penwest Pharmaceuticals Co....
BioCentury | Aug 23, 2010
Analyst Picks & Changes

Analyst picks & changes

...time. He estimates peak sales could reach $800M, assuming no generic competition. Endo is acquiring Penwest Pharmaceuticals Co....
BioCentury | Aug 16, 2010
Company News

Endo, Penwest deal

...Endo will acquire partner Penwest in a tender offer of $5 per share, or about $168...
...ER oxymorphone, for which Penwest receives royalties under a 1997 deal. Endo also will gain Penwest's...
...advising Penwest, and Lazard is advising Endo. Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP), Chadds Ford, Pa Penwest Pharmaceuticals Co....
Items per page:
1 - 10 of 161
BioCentury | Jul 21, 2014
Clinical News

Nalbuphine ER: Phase II/III started

...rights to the compound from Endo, which gained the rights through its 2010 acquisition of Penwest Pharmaceuticals Co....
BioCentury | Jul 14, 2014
Clinical News

Nalbuphine ER: Phase I data

...to the product in 2011 from Endo, which gained rights from its 2010 acquisition of Penwest Pharmaceuticals Co....
BioCentury | Jun 5, 2014
Financial News

Trevi closes $15 million of $25 million series B

...from Endo International plc (NASDAQ:ENDP; TSX:ENL), which gained the rights from its 2010 acquisition of Penwest Pharmaceuticals Co....
BioCentury | May 13, 2013
Clinical News

Nalbuphine ER: Phase I started

...the compound in 2011 from Endo, which gained the rights from its 2010 acquisition of Penwest Pharmaceuticals Co....
BioCentury | Jan 14, 2013
Emerging Company Profile

Trevi: Pain to itch

...from Endo Health Solutions Inc. , which gained the rights from its 2010 acquisition of Penwest Pharmaceuticals Co....
...submitted patent applications covering the oral formulation of nalbuphine and the method of treating pruritus. Penwest...
...CEO of Penwest. Good said she and Trevi CMO Thomas Sciascia, who was CMO at Penwest...
BioCentury | Oct 8, 2012
Product Development

Boosting mitochondria

...Penwest Therapeutics Inc., but Miller said that deal ended when Endo Health Solutions Inc. acquired Penwest...
BioCentury | Aug 27, 2012
Finance

Seeking alpha

...Corp. (NASDAQ:EPCT), which he helped take public in 2006, and president of drug delivery play Penwest Pharmaceuticals Co....
BioCentury | Sep 27, 2010
Company News

Endo, Penwest deal

...Endo completed its initial tender offer for Penwest, acquiring about 30.8 million shares (82.8%) at $5...
...complete next quarter (see BioCentury, Aug. 16). Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP), Chadds Ford, Pa. Penwest Pharmaceuticals Co....
BioCentury | Aug 23, 2010
Analyst Picks & Changes

Analyst picks & changes

...time. He estimates peak sales could reach $800M, assuming no generic competition. Endo is acquiring Penwest Pharmaceuticals Co....
BioCentury | Aug 16, 2010
Company News

Endo, Penwest deal

...Endo will acquire partner Penwest in a tender offer of $5 per share, or about $168...
...ER oxymorphone, for which Penwest receives royalties under a 1997 deal. Endo also will gain Penwest's...
...advising Penwest, and Lazard is advising Endo. Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP), Chadds Ford, Pa Penwest Pharmaceuticals Co....
Items per page:
1 - 10 of 161